266 results about "TB bacillus" patented technology

The invention belongs to the field of biomedicine examination, and particularly relates to a kit and a method for detecting mycobacterium tuberculosis infection and application. The invention discloses a novel mycobacterium tuberculosis detection reagent by screening specific T cell epitope of mycobacterium tuberculosis, wherein the reagent contains polypeptide or analog thereof represented by SEQ ID No.1-10. The method detects cell factors released from T cells by using single or more SEQ ID No.1-10 polypeptides to contact the T cells of mycobacterium tuberculosis infected individuals. The method can effectively detect active tuberculosis or latent tuberculosis infection, and is free from disturbance of Bacilli Calmette Guerin (BCG) inoculation vaccines. The invention also discloses a diagnostic kit and other application based on the polypeptide and the method. Compared with the gamma interferon release experiments in the prior art, the method can obviously improve the detection rate without reducing the specificity and has high clinical application value.

The invention belongs to the technical field of protein structure prediction and drug molecule virtual screening, specifically to a method for screening a compound with targeted action on an inactive conformation of a protein kinase. The method provided by the invention comprises a prediction method for the conformation of an active chain section of the protein kinase, wherein a corresponding DFG-out inactive conformation is generated from the DFG-in active conformation of the protein kinase; the method also comprises a selection method of a combined conformation after implementing butt joint of a II type inhibitor, and the selection method is used for selecting small molecules in conformation prediction and virtual screening. The method for screening a compound with targeted action on an inactive conformation of a protein kinase is already calculated and verified in the protein kinases of seven types of known inactive conformations, wherein the success rate is close to 96%. The method provided by the invention is already applied to the prediction of inactive conformation of PknB protein kinase of tubercle bacillus and the virtual screening of a possible II type inhibitor of PknB, and the bacteriostasis of two kinds of small molecules are already found according to bacteriostatic experiments.

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention discloses a reagent for detecting tubercle bacillus infection in vitro and a method thereof. The reagent comprises M233 polypeptide represented by SEQ ID No.1; and cytokine released from T cells is detected by contacting the M233 polypeptide or an analog thereof with the T cells of a tubercle bacillus host to determine whether the T cells identify the M233 polypeptide or the analog thereof. The reagent has the advantages of high sensitivity, good specificity, being free from interference of BCG vaccine and non-tuberculosis mycobacteria vaccine, being capable of detecting active pulmonary tuberculosis patients, the patients with dormant infection and healthy persons who contact with mycobacterium nontuberculosis. The reagent and the method are especially applicable to detecting tuberculosis and/or dormant infection thereof for Chinese people.

The invention discloses a method for quickly detecting mycobacterium tuberculosis, which comprises the following steps: 1, infecting phage with the mycobacterium tuberculosis; 2, killing the phage notinfecting outside the mycobacterium tuberculosis; 3, amplifying the infecting phage; and 4, after labeling gold with antiphage antibody, adopting quick immunochromatography to detect whether the phage exists or not so as to judge whether the mycobacterium tuberculosis exists in a sample. In addition, the invention also discloses a corresponding kit, which comprises sample treating fluid, proliferous liquid, a killing agent, mycobacterium smegmatis, mycobacteriophages and a phage colloidal gold method immunity-chromatography test pen. The method and the kit can quickly and accurately detect the mycobacterium tuberculosis so as to meet the requirement of quickly diagnosing pulmonary tuberculosis and timely medicate the patient.

The invention belongs to the technical field of pharmaceutical chemistry and discloses a quinoline, and a preparation method and an application of the quinoline. The quinoline is a chemical compound shown as Formula I as shown in the specification, or an optical isomer, racemate, a diastereoisomer, pharmaceutically acceptable salt or solvate of the chemical compound. The quinoline has a significant killing effect on mycobacterium tuberculosis, is applicable to preparing drugs for treating or preventing diseases or symptoms caused by mycobacterium tuberculosis infection.

The invention discloses a method and a kit for detecting drug resistance of mycobacterium tuberculosis. The invention provides special-purpose primers and special-purpose probes for identification of drug resistance of mycobacterium tuberculosis in a sample needing to be detected, wherein the special-purpose primers comprise multiple primer groups; each one of the primer groups comprises a commonprimer and multiple specific primers for amplification of alleles corresponding to all mutational sites of same-purpose genes; the special-purpose probes comprise multiple types of probes; and each one of the probes specifically binds with target sequences corresponding to the common primer and the specific primers of the primer group. Experiments of the invention prove that the special-purpose primers and the special-purpose probes can be combined by an efficient and sensitive duplex Taqman real-time fluorescent polymerase chain reaction (PCR) technology and a sequence specific primer (SSP) amplification technology so that drug resistance of mycobacterium tuberculosis in a detected sample can be detected in a short time.

The present invention belongs to the field of screening antituberculotic target, vaccine antigen and detecting target in molecular biological technology, and is especially process of screening protein resisting rifampicin as antituberculotic. The process includes the first culturing drug resistant strain, the subsequent separating protein of drug resistant strain from protein of sensitive strain, comparing protein of drug resistant strain and protein of sensitive strain to determine the drug resistant protein, and final separating and identifying drug resistant protein. The process of the present invention can separate and identify drug resistant protein of Mycobacterium tuberculosis to provide new way for further understanding the drug resisting mechanism of Mycobacterium tuberculosis, fast clinical detection of drug resistant strain, and developing vaccine and medicine.

The invention belongs to the technical field of medical treatment, and in particular relates to a purification method of tubercle bacilipin Arab mannan (LAM) and a tubercle bacillus diagnostic reagent. In the invention, by utilizing the structural differences that the LAM antigen contains three mannose while other impurities (LM, PIM, and the like) only contain one mannose, and the appetency of lectin (such as flat lentils lectin) to three manna branch structures is far higher than two manna and one manna, the LAM antigen purification is carried out by using the lectin to obtain the LAM antigen with the purity of above 95%. The high-purity antigen obtained by purification can form a reagent for LAM antigen detection and can also form a reagent for enriching urine LAM antigen, purifying LAM antibody and detecting the urine LAM antibody.

The invention discloses a preparation method of agilawood health-care wine, which comprises the following steps: 1) raw material preparation; 2) infusion; 3) finished product preparation, that is, filtering and checking infused liquid, then bottling and sealing to prepare the agilawood health-care wine. The invention also discloses agilawood wine prepared by the method. The method provided by the invention is simple in preparation process, easy to realize, high in production efficiency, and capable of rapidly preparing agilawood health-care wine with good health-care effect. The agilawood wine provided in the invention is simple in raw material components, and reasonable in combination, and gives full and effective play to pharmacological effects of agilawood, which means that fragrance and pharmacological components of agilawood are effectively diffused into the wine; the wine has the efficacy of inhibiting mycobacterium tuberculosis, organizing central nervous system, calming, relieving cough, reducing high blood pressure, and resisting heart ischemia, and thus has the effect of health care.

The invention relates to the biological technology field, and provides a preparation method for an ELISA detection kit of goat corynebacterium pseudotuberculosis antibodies. Complete corynebacterium pseudotuberculosis thalluses are employed as coating antigens, an indirect ELISA detection method is established, whether serum contains corynebacterium pseudotuberculosis antibodies is detected and whether a goat is infected with caseous lymphadenitis is determined. The positive and negative critical value is determined, and the detection kit has high specificity and repetition, can detect pseudotuberculosis antibodies in goat serum rapidly and effectively, and can be used for goat pseudotuberculosis diagnosis and epidemiological investigation.

The present invention provides a nanometer probe system for tubercle bacillus detection, and a preparation method for the nanometer probe, and further provides a tubercle bacillus detection method based on the nanometer probe system and the preparation method. The nanometer probe system comprises an integrated nanometer material probe and immunomagnetic beads, wherein the integrated nanometer material probe, the immunomagnetic beads and tubercle bacillus thallus are combined through specific ligands to form a tertiary complex, a magnetic field effect is adopted to rapidly and accurately separate and concentrate the tubercle bacillus and the integrated nanometer probe, a fluorescence signal on the integrated probe is detected, and the detection signal can be significantly amplified through magnetic enrichment and quantity difference between polypeptide sites and fluorescence quantum dots on the integrated nanometer probe so as to achieve accurate, highly sensitive and specific tubercle bacillus detection.

The invention discloses a reagent for mycobacterium tuberculosis infection detection, clinical treatment effect tracking and antituberculous vaccine development. The novel mycobacterium tuberculosis derived reagent Rv3006 (LPPZ) prepared by a gamma-interferon gamma release assay and enzyme linked immunosorbent assay comprises antigen or polypeptide and analogues thereof, wherein terminal C to terminal N in the amino acid sequence of the Rv3006 antigen is as shown in SEQ ID NO:1. By utilizing the reagent, tuberculous patients in the active phase and tuberculous latent infectors can be well detected; the specific immune response of Rv3006 is reduced along with treatment development and disease condition remission, which indicates that the reagent can be used for well tracking the clinical treatment situation of a tuberculous patient, thus having a good clinical application prospect. Furthermore, the reagent has a protective effect on a mouse infected by a mycobacterium tuberculosis standard toxic strain H37Rv, thus having a good development prospect of antituberculous vaccines.